Skip to main content

Table 4 Regimens used for salvage therapy, per country

From: Management and treatment of relapsed or refractory Ph(−) B-precursor ALL: a web-based, double-blind survey of EU clinicians

Regimen

Number of respondents, na,b

 

France

Germany

Italy

Spain

UK

Total, n (%)

N = 15

N = 15

N = 15

N = 15

N = 15

N = 75

Published regimens

 Augmented hyper-CVAD

3

1

2

5

 

11 (15)

 CALGB 8811/Larson

1

1

1

  

3 (4)

 EORTC ALL-3 (induction phase)

1

 

2

  

3 (4)

 FLAG-AMSA

 

1

  

1

2 (3)

 FLAG-IDA

 

1

 

2

6

9 (12)

 GMALL 07/03

 

6

1

  

7 (9)

 GRAALL 02/2005 (salvage phase)

2

1

   

3 (4)

 GRAALL 2003 (salvage phase)

1

2

   

3 (4)

 Hyper-CVAD

 

1

1

1

1

4 (5)

 MRC UK ALL XII/ECOG 2993

  

1

 

3

4 (5)

 PETHEMA ALL-96

   

2

 

2 (3)

Modified published regimens

 FLAG-IDA

   

1

2

3 (4)

  1. aRespondents could select multiple guidelines regimens
  2. bPublished regimens reported by one respondent were: EORTC ALL3 (salvage); GIMEMA 0288 (induction phase); GIMEMA 0288 (salvage); GIMEMA-LAL0904 (induction phase); GIMEMA-LAL0904 (salvage); GRAALL 02/2005 (induction phase); LALA-94; nelarabine/cyclophosphamide; PALG 5–2007 (Induction II); VANDEVOL; modified published regimens reported by one respondent were: aBFM; augmented hyper-CVAD; CALGB 8811/Larson; GRAALL 02/2005 (induction phase); LALA-94; MRC UK ALL XII/ECOG 2993; PETHEMA ALL-96; RWGALS – NP1 (Induction I); VANDEVOL; ongoing clinical trials reported by one respondent were: NCT01564784 and UKALL 2011 trial
  3. aBFM, augmented Berlin-Frankfurt-Muenster; ALL, acute lymphoblastic leukaemia; CALGB, Cancer and Leukemia Group B; CVAD, cyclophosphamide, vincristine, doxorubicin (Adriamycin), dexamethasone; ECOG, Eastern Cooperative Oncology Group; EORTC, European Organization for Research and Treatment of Cancer; FLAG-AMSA, fludarabine, high-dose cytarabine, granulocyte colony-stimulating factor-amsacrine; FLAG-IDA, fludarabine, high-dose cytarabine, granulocyte colony-stimulating factor-idarubicin; GIMEMA, Gruppo Italiano Malattie EMatologiche dell’Adulto (Italian Group for Haematological Diseases in Adults); GMALL, German Multicenter Study Group for Adult ALL; GRAALL, Group for Research in Adult Acute Lymphoblastic Leukemia; LALA, Leucémie Aiguës Lymphoblastique de l’Adulte (Acute Lymphoblastic Leukemia in Adults); MRC UKALL XII, Medical Research Council Acute Lymphoblastic Leukemia Trial XII; PALG, Polish Adult Leukemia Group; PETHEMA, Programa para el Estudio de la Terapéutica en Hemopatía Maligna (Program for Study and Treatment of Malignant Hemopathies); RWGALS-NP1, Romanian Working Group for Acute Leukemia Study National Protocol 1; VANDEVOL, etoposide, clofarabine, asparaginase, mitoxantrone, and dexamethasone
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us